Last week, European Medicines Agency (EMA) updated the guidance document “European Medicines Agency post-authorisation procedural advice for users of the centralised procedure”.
This guidance document addresses a number of issues that marketing authorisation holders (MAHs) may have on post-approval procedures and provides an overview of the Agency’s position on issues, which are often addressed in evaluations or meetings with MAHs in the post-approval phase.
The Agency regularly updates this document to reflect new developments, to include guidance on further post-approval procedures and to reflect the implementation of the new European legislation.
Asphalion has extensive experience with Centralised Procedures (CP). If you are planning a CP for Marketing Authorisation Application (MAA) or about to initiate a post-authorisation procedure for products approved through CP and would like to have support, please contact us at info@asphalion.com
Un estudio con datos de los últimos 35 años, ind...
Un equipo de investigadores de la Universidad Juli...
A new technique allows the design of solid materia...
En nuestro post hablamos sobre este interesante tipo de célula del si...
Han desarrollado un estudio para evaluar la correlación entre el teji...
Portal de biotecnología en España
¡Suscríbase a nuestro newsletter para estar al día con las últimas noticias y ofertas!
2013 © Biotech-Spain.com - Site Developments SL. Todos los derechos reservados. Terminos y Condiciones | Política de Privacidad
Articles
Directory